通过网络药理学、转录组学及功能验证揭示“一味消积汤”在非小细胞肺癌(NSCLC)中的多靶点作用机制
Deciphering the multi-target mechanism of Yifei Xiaoji decoction in NSCLC through network pharmacology, transcriptomics, and functional validation
Cihan Wang, Jian Wu, Kang Feng, Yang Bao, Jianming Lu, Ouyang Zhang, Junying Jiang, Qifeng Song, Guangzheng Zhu, Yuntao Tang, Peihe Wang, Xiaopeng Yang, Hong Guo, Wei Wang, Chenlong Yi
Journal:Results in Chemistry
IF:5.8
DOI:10.1016/j.rechem.2026.103777
PMID:
Published:2026-08-18
research field:氧化还原生物学靶向治疗肾脏病理生理学金属稳态纳米医学
Abstract
Background Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death. Yifei Xiaoji Decoction (YXD) shows clinical benefits for advanced NSCLC, but its mechanisms are not fully understood. Materials and methods Network pharmacology and transcriptomics of YXD-treated tumors were integrated to identify core targets. Molecular docking assessed binding affinity. In vivo efficacy was evaluated in a Lewis lung carcinoma syngeneic model. In vitro assays measured cell viability, apoptosis, mitochondrial function (Ca 2+ flux and membrane potential), and PI3K/AKT/Bax/Bcl-2 protein expression. Results YXD simultaneously regulated the PI3K/AKT pathway and mitochondrial calcium homeostasis. It inhibited tumor growth in a dose-dependent manner, promoted apoptosis in vivo, and suppressed cell viability while triggering mitochondrial calcium overload in vitro. Western blot confirmed that YXD suppressed PI3K/AKT phosphorylation and increased the Bax/Bcl-2 ratio. Conclusion YXD promotes NSCLC apoptosis by inhibiting the PI3K/AKT survival pathway and disrupting mitochondrial calcium signaling, providing a scientific basis for its use as an auxiliary NSCLC treatment.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


